Researcher
Evangelia Bolli
- Keywords:Applied biological sciences, biotechnology
Affiliations
- Cellular and Molecular Immunology (Research group)
Member
From1 Jul 2019 → 12 Aug 2019 - Department of Bio-engineering Sciences (Department)
Member
From8 Apr 2019 → 30 Jun 2019 - Faculty of Sciences and Bioengineering Sciences (Faculty)
Member
From31 Aug 2015 → 19 Jun 2019 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2014 → 30 Jun 2019 - Faculty of Sciences and Bioengineering Sciences (Faculty)
Member
From20 Sep 2012 → 12 Sep 2014
Projects
1 - 1 of 1
- Nanobody-based depletion of protumoral tumor-associated macrophages as novel cancer therapy.From1 Jan 2015 → 1 Oct 2018Funding: IWT personal funding - strategic basic research grants
Publications
1 - 10 of 13
- Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting(2023)
Authors: Marco Erreni, Francesca D'Autilia, Roberta Avigni, Evangelia Bolli, Sana M Arnouk, Kiavash Movahedi, Pieterjan Debie, Achille Anselmo, Raffaella Parente, Cécile Vincke, et al.
Pages: 355-373 - IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D(2021)
Authors: Máté Kiss, Lieselotte Vande Walle, Pedro H V Saavedra, Els Lebegge, Helena Van Damme, Aleksandar Murgaski, Junbin Qian, Manuel Ehling, Samantha Pretto, Evangelia Bolli, et al.
Pages: 309-323 - Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy(2021)
Authors: Helena Van Damme, Bruno Dombrecht, Máté Kiss, Heleen Roose, Elizabeth Allen, Eva Van Overmeire, Daliya Kancheva, Liesbet Martens, Aleksandar Murgaski, Pauline Bardet, et al.
- Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels.(2020)
Authors: Maximilian Scherger, Evangelia Bolli, Judith Stickdorn, Alexandra Van Driessche, Hansjörg Schild, Stephan Grabbe, Bruno De Geest, Lutz Nuhn
- Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors(2019)
Authors: Evangelia Bolli, Matthias D'Huyvetter, Aleksandar Murgaski, Danielle Berus, Geert Stangé, Emile Clappaert, Sana M Arnouk, Ana Rita Pombo Antunes, Ahmet Krasniqi, Tony Lahoutte, et al.
Pages: 1-11 - Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages(2019)
Authors: Catarina Xavier, Anneleen Blykers, Damya Laoui, Evangelia Bolli, Ilse Vaneycken, Jessica Bridoux, Henri Vincent Baudhuin, Geert Raes, Hendrik Everaert, Kiavash Movahedi, et al.
Pages: 898-906 - Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages(2019)
Authors: Yannick De Vlaeminck, Quentin Lecocq, Philippe Giron, Xenia Geeraerts, Steve Schoonooghe, Kiavash Movahedi, Sam Massa, Evangelia Bolli, Cleo Goyvaerts, Jo Van Ginderachter, et al.
Pages: 107-120 - Nanobody-mediated targeting of tumor-associated macrophages for cancer therapy(2019)
Authors: Evangelia Bolli, Jo Van Ginderachter
- Targeting Protumoral Tumor-Associated Macrophages with Nanobody-Functionalized Nanogels through Strain Promoted Azide Alkyne Cycloaddition Ligation(2018)
Authors: Lutz Nuhn, Evangelia Bolli, Sam Massa, Isabel Vandenberghe, Kiavash Movahedi, Bart Devreese, Jo Van Ginderachter, Bruno G De Geest
Pages: 2394–2405 - Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages(2018)
Authors: Stefano Bonelli, Xenia Geeraerts, Evangelia Bolli, Jiri Keirsse, Máté Kiss, Ana Rita Pombo Antunes, Helena Van Damme, Karen De Vlaminck, Kiavash Movahedi, Damya Laoui, et al.
Pages: 777-787